Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan unveils generic version of Boniva
The product, a generic equivalent to Roche’s Boniva, is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Boniva had US sales of approximately $517m for
The product, a generic equivalent to Roche’s Boniva, is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Boniva had US sales of approximately $517m for
In RENAISSANCE 4 and RENAISSANCE 5, efficacy and tolerability studies, patients did not respond adequately to initial antidepressant treatment. The studies did not meet the primary endpoint of
The company expects to launch Altrazeal in six additional markets for human and veterinary use, in the near future. The company also expects to receive approval in the
The extension will allow the existing ten Nanobody programs to advance to a stage where Boehringer can progress each program into development. Ablynx will receive a total of
Both the parties will select between five and ten projects, decided on by a committee of UCB and Oxford University representatives, InPharm reported. UCB’s immunology research center currently
The randomized, open-label, dose-finding study will evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamic poperties of the growth harmone. The trial will compare the 12-month growth velocity of
As per the agreement, Actavis has exclusive rights to commercialize and further develop MoxDuo IR for the US market. Actavis will assume all costs for product launch as
The study compared safety and efficacy of three dose levels of PH-10 (0.002%, 0.005% and 0.01% Rose Bengal) against vehicle. The Phase II trial had randomised ninety-nine patients
The company introduces a portfolio of five Mosaic Multiplex lung cancer kits for use in tissue analysis of suspected lung cancer patients. Mosaic Multiplex kits will allow testing
The transaction is expected to close at the end of March 2012. KCR will be combined with inVentiv’s existing functional service provider (FSP) and staffing businesses within the